CymitQuimica logo

CAS 158930-09-7

:

Frovatriptan Succinate

Description:
Frovatriptan succinate is a selective serotonin receptor agonist, primarily used in the treatment of migraine headaches. It acts on the 5-HT_1B and 5-HT_1D serotonin receptors, leading to vasoconstriction of cranial blood vessels and inhibition of pro-inflammatory neuropeptide release. This compound is characterized by its relatively long half-life compared to other triptans, allowing for sustained relief from migraine symptoms. Frovatriptan is typically administered orally and is known for its favorable side effect profile, which includes a lower incidence of rebound headaches. The succinate salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. In terms of physical properties, it is a white to off-white crystalline powder, and its solubility varies in different solvents. As with any medication, it is essential to consider contraindications and potential interactions with other drugs. Overall, frovatriptan succinate represents an important option in the acute management of migraines, particularly for patients who may benefit from its longer duration of action.
Formula:C18H23N3O5
InChI:InChI=1/C14H17N3O.C4H6O4/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13;5-3(6)1-2-4(7)8/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18);1-2H2,(H,5,6)(H,7,8)/t9-;/m1./s1
SMILES:CN[C@@H]1CCc2c(C1)c1cc(ccc1[nH]2)C(=N)O.C(CC(=O)O)C(=O)O
Synonyms:
  • SB-209509ax
  • Vml 251
  • 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-, butanedioate (1:1)
  • 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-, butanedioate (1:1)
  • Butanedioic acid, compd. with (3R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide (1:1)
  • (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide butanedioate (1:1)
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.